Analysis confirms crizotinib's second-line efficacy in Asian NSCLC patients
This article was originally published in Scrip
An analysis of data from a Phase III clinical trial with Pfizer's Xalkori (crizotinib) has confirmed the efficacy and safety of the oral anaplastic lymphoma kinase (ALK) inhibitor in Asian patients with advanced ALK-positive non-small cell lung cancer (NSCLC).
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.